Target
MET exon 14
1 product
7 abstracts
Abstract
Real-world outcomes comparison between the MET inhibitors (METi) capmatinib and tepotinib in patients with stage IV non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation.Org: Mayo Clinic Florida, Mayo Clinic,
Abstract
A real-world study on biomarker retesting among patients with non-small cell lung cancer and disparity in outcomes.Org: AbbVie Inc., North Chicago, IL, Perelman School of Medicine at the University of Pennsylvania, Abramson Cancer Center, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,
Product
TMZAbstract
LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer.Org: NeoGenomics Ltd, Cambridge, United Kingdom, Medipole Lyon Villeurbanne, Villeurbanne, France, Infirmerie Protestante, Caluire Et Cuire, France, Institut de Cancérologie Strasbourg Europe ICANS, Strasbourg, France,
Abstract
Utility of ctDNA tumor fraction to inform negative liquid biopsy (LBx) results and need for tissue reflex in advanced non-small cell lung cancer (aNSCLC).Org: Foundation Medicine, Inc., Cambridge, MA, UC San Diego Moores Cancer Center,
Abstract
FDA analysis of toxicity profiles of oral TKIs recently approved for non-small cell lung cancer based on receipt of prior immune checkpoint inhibitor therapy.Org: United States Food and Drug Administration, Center for Drug Evaluation and Research, Oncology Center of Excellence,
Abstract
Genomic biomarker testing and treatment in advanced NSCLC: Practice patterns and barriers in a global survey of oncology point-of-care mobile app users.Org: Siyemi Learning, ONCOassist, Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom,
Abstract
Prevalence of actionable oncogenic alterations (AGA) among patients with advanced (adv) non-squamous (NSQ) non-small cell lung cancer (NSCLC) by age, sex, and race in the United States (US).Org: Merck & Co, Inc., Merck & Co., Inc., Merck and Co, Inc.,